Compass Pathways Psilocybin Patent Upheld
Compass Pathways scores a major victory in their bid to patent Comp 360, a proprietary formulation of psilocybin.
Psychedelic Spotlight News
-
-
Jon Stewart Admits to Week Long Mushroom Binge before Comedy Set
Jon Stewart, comedian and former host of “The Daily Show,” drops a shroom bomb in a recent podcast interview.
-
I Tried 5-MeO-DMT at a Psychedelic Retreat. This is MY Story
Have you ever considered taking 5-MeO-DMT, also known as Bufo…
-
The Great Microdosing Debate
Microdosing psychedelics is more popular than ever, but is there any evidence that it works? We unpack the great microdosing debate.
-
Psilocybin as an Agent for Human and Cultural Development with Jahan Khamsehzadeh Ph.D.
In this episode, Dr. Khamsehzadeh delves into our historical and ancestral relationship to psilocybin and theorizes how mushrooms have impacted the development of the brain.
-
AI Interview on Psychedelics
There is growing interest in AI’s ability to mimic human interactions. We interview OpenAI’s GPT-3 chatbot to see what it knows about psychedelics.
-
Can Ketamine Therapy Be the Solution for Treatment Resistant Depression & Opioid Addiction?
Ketamine therapy is shaping up to be one of the…
-
DMT is Effective at Treating Depression, New Study Finds
DMT is a powerful hallucinogen that can conjure visions of entities and alien worlds, but new research shows it can also treat depression.
-
Cybin Acquires Entheon’s DMT Trial, Numi’s Novamind Acq. Complete, Bad News for MindMed and More
This week in psychedelic business news: Cybin acquires a Phase…
-
Is the Mystical Experience Necessary for Psychedelic Therapy?
Recent research suggests that mystical experiences may be one of the best predictors of positive outcomes in psychedelic therapy.
